Ireland
# |
Name |
EBIT Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
26.73%
|
Dec. 31, 2023 | USD 31.53 | -1.19% |
|
Ireland |
|
2 |
15.32%
|
Dec. 31, 2023 | USD 124.37 | -0.54% |
|
Ireland |
|
3 |
11.52%
|
Dec. 31, 2023 | USD 199.08 | -1.31% |
|
Ireland |
|
4 |
6.62%
|
Dec. 31, 2023 | USD 70.72 | 0.21% |
|
Ireland |
|
5 |
-209.08%
|
Dec. 31, 2023 | USD 14.23 | -3.20% |
|
Ireland |
|
6 |
-539.61%
|
Dec. 31, 2023 | USD 7.90 | 2.73% |
|
Ireland |
The Clinical Trials company in Ireland with the highest EBIT Margin is Alkermes plc (NasdaqGS: ALKS) at 26.73%.
The Clinical Trials company in Ireland with the lowest EBIT Margin is Avadel Pharmaceuticals plc (NasdaqGM: AVDL) at -539.61%.
The top 10 Clinical Trials companies in Ireland by EBIT Margin are Alkermes plc, Jazz Pharmaceuticals plc, ICON Public Limited Company, Cosmo Pharmaceuticals N.V., Prothena Corporation plc and Avadel Pharmaceuticals plc.
The bottom 10 Clinical Trials companies in Ireland by EBIT Margin are Avadel Pharmaceuticals plc, Prothena Corporation plc, Cosmo Pharmaceuticals N.V., ICON Public Limited Company, Jazz Pharmaceuticals plc and Alkermes plc.